These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38377526)

  • 1. High Probability of Gene-Drug Interactions Associated with Medication Side Effects in Adolescent Depression: Results from a Randomized Controlled Trial of Pharmacogenetic Testing.
    Nooraeen S; Croarkin PE; Geske JR; Shekunov J; Orth SS; Romanowicz M; Frye MA; Vande Voort JL
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):28-33. PubMed ID: 38377526
    [No Abstract]   [Full Text] [Related]  

  • 2. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression.
    Vande Voort JL; Orth SS; Shekunov J; Romanowicz M; Geske JR; Ward JA; Leibman NI; Frye MA; Croarkin PE
    J Am Acad Child Adolesc Psychiatry; 2022 Jan; 61(1):46-55. PubMed ID: 34099307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Beyond Red Light, Green Light: Examining the Role of Pharmacogenomics in Evidence-Based Care in Child and Adolescent Psychiatry.
    Namerow LB; Ramsey LB; Malik S; Cortese S; Strawn JR
    J Am Acad Child Adolesc Psychiatry; 2022 Jan; 61(1):29-31. PubMed ID: 34767918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.
    Forester BP; Parikh SV; Weisenbach S; Ajilore O; Vahia I; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Shelton RC; Macaluso M; Li J; Traxler P; Logan J; Brown L; Dechairo B; Greden JF
    Am J Geriatr Psychiatry; 2020 Sep; 28(9):933-945. PubMed ID: 32513518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.
    Thase ME; Parikh SV; Rothschild AJ; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M; Li J; Brown K; Jablonski MR; Greden JF
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31721487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
    Oslin DW; Lynch KG; Shih MC; Ingram EP; Wray LO; Chapman SR; Kranzler HR; Gelernter J; Pyne JM; Stone A; DuVall SL; Lehmann LS; Thase ME; ; Aslam M; Batki SL; Bjork JM; Blow FC; Brenner LA; Chen P; Desai S; Dieperink EW; Fears SC; Fuller MA; Goodman CS; Graham DP; Haas GL; Hamner MB; Helstrom AW; Hurley RA; Icardi MS; Jurjus GJ; Kilbourne AM; Kreyenbuhl J; Lache DJ; Lieske SP; Lynch JA; Meyer LJ; Montalvo C; Muralidhar S; Ostacher MJ; Paschall GY; Pfeiffer PN; Prieto S; Przygodzki RM; Ranganathan M; Rodriguez-Suarez MM; Roggenkamp H; Schichman SA; Schneeweis JS; Simonetti JA; Steinhauer SR; Suppes T; Umbert MA; Vassy JL; Voora D; Wiechers IR; Wood AE
    JAMA; 2022 Jul; 328(2):151-161. PubMed ID: 35819423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.
    Winner JG; Carhart JM; Altar CA; Allen JD; Dechairo BM
    Discov Med; 2013 Nov; 16(89):219-27. PubMed ID: 24229738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.
    Groessl EJ; Tally SR; Hillery N; Maciel A; Garces JA
    J Manag Care Spec Pharm; 2018 Aug; 24(8):726-734. PubMed ID: 30058980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
    Pérez V; Salavert A; Espadaler J; Tuson M; Saiz-Ruiz J; Sáez-Navarro C; Bobes J; Baca-García E; Vieta E; Olivares JM; Rodriguez-Jimenez R; Villagrán JM; Gascón J; Cañete-Crespillo J; Solé M; Saiz PA; Ibáñez Á; de Diego-Adeliño J; ; Menchón JM
    BMC Psychiatry; 2017 Jul; 17(1):250. PubMed ID: 28705252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.
    Rothschild AJ; Parikh SV; Hain D; Law R; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Shelton RC; Macaluso M; Brown K; Lewis D; Gutin A; Jablonski MR; Greden JF
    Psychiatry Res; 2021 Feb; 296():113649. PubMed ID: 33360967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
    Rosenblat JD; Lee Y; McIntyre RS
    J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
    Bousman CA; Arandjelovic K; Mancuso SG; Eyre HA; Dunlop BW
    Pharmacogenomics; 2019 Jan; 20(1):37-47. PubMed ID: 30520364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of PHQ-9 and pharmacogenetic testing in clinical practice.
    Kierce ED; Vanderhoef DM; Connors LM
    J Am Assoc Nurse Pract; 2019 Sep; 31(9):497-501. PubMed ID: 30829971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression.
    McCarthy MJ; Chen Y; Demodena A; Leckband SG; Fischer E; Golshan S; Suppes T; Kelsoe JR
    J Psychopharmacol; 2021 Aug; 35(8):992-1002. PubMed ID: 33938307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing.
    Zeier Z; Carpenter LL; Kalin NH; Rodriguez CI; McDonald WM; Widge AS; Nemeroff CB
    Am J Psychiatry; 2018 Sep; 175(9):873-886. PubMed ID: 29690793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study.
    Tonozzi TR; Braunstein GD; Kammesheidt A; Curran C; Golshan S; Kelsoe J
    Pharmacogenomics; 2018 Oct; 19(15):1169-1179. PubMed ID: 30207201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of Pharmacogenetic Testing to Modeled Medication Change Recommendations in a Long-Term Care Population with Polypharmacy.
    Sugarman EA; Cullors A; Centeno J; Taylor D
    Drugs Aging; 2016 Dec; 33(12):929-936. PubMed ID: 27826798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Utility of Pharmacogenetic Testing and a Clinical Decision Support Tool to Enhance the Identification of Drug Therapy Problems Through Medication Therapy Management in Polypharmacy Patients.
    Kim K; Magness JW; Nelson R; Baron V; Brixner DI
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1250-1259. PubMed ID: 30479202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.